Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Drug Administration and Therapy Phases: Overview

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Prospective evaluation of genomics-guided off-label treatment.

Nature·2026

Same author

Prediction of Mutations and Outcome in Gastrointestinal Stromal Tumors with Deep Learning: A Multicenter, Multinational Study.

medRxiv : the preprint server for health sciences·2026

Same author

Health-related quality of life in patients with gastrointestinal stromal tumor: data from a real-world cohort compared with a normative population.

ESMO real world data and digital oncology·2026

Same author

A comprehensive assessment of the existing landscape of personalized cancer medicine in the European Union, on behalf of the PCM4EU consortium.

ESMO open·2025

Same author

Corrigendum to "Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)": [Ann Oncol 26 (2015) 2168-2173].

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Same author

Expression of antibody-drug conjugate targets in soft tissue sarcomas.

ESMO open·2025

Search research articles

Related Experiment Video

Updated: May 20, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Adjuvant therapy in primary GIST: state-of-the-art.

P Reichardt¹, J-Y Blay², I Boukovinas³

¹Interdisciplinary Oncology, HELIOS Klinikum Berlin-Buch, Berlin, Germany.

Annals of Oncology : Official Journal of the European Society for Medical Oncology

|July 27, 2012

Summary

Adjuvant imatinib 400 mg/day for 3 years is standard for high-risk gastrointestinal stromal tumors (GISTs). Expert recommendations cover patient selection, mutational analysis, and follow-up to optimize GIST management.

Related Experiment Videos

Last Updated: May 20, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Area of Science:

Oncology
Medical Research

Background:

Management of primary gastrointestinal stromal tumors (GISTs) has evolved with adjuvant therapy.
Recent trial results significantly impact evidence for adjuvant therapy duration in GISTs.

Purpose of the Study:

To describe optimal management and best practices for systemic adjuvant treatment of primary GISTs.
To formulate recommendations based on current evidence for GIST adjuvant therapy.

Main Methods:

A European Expert Panel reviewed current literature on adjuvant therapy for primary GISTs.
Experts formulated recommendations for GIST management based on quality evidence.

Main Results:

Adjuvant imatinib 400 mg/day for 3 years is standard for high-risk GISTs.
Patient selection for adjuvant therapy should use risk stratification schemes.
Mutational analysis is recommended; imatinib is not recommended for D842V-mutated GISTs.
Follow-up includes regular clinical assessments and CT scans for up to 10 years.

Conclusions:

Key points in systemic adjuvant treatment and clinical management of primary GISTs were identified.
Open questions in GIST management were highlighted by the expert panel.